A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

NCT07712523 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Subjects With Non-Segmental Vitiligo

Interventions

DRUG: QY201 Tablets(5mg）
DRUG: QY201 Tablets（10mg）
DRUG: QY201 Tablets（20mg）
DRUG: QY201 Placebo Tablets

Sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.